Apotex Pharmachem

Apotex Pharmachem is the active pharmaceutical ingredient (API) division of Apotex, specializing in the development and manufacturing of high-quality synthetic APIs for the global generic pharmaceutical market. Headquartered in Brantford, Canada, the company operates one of the country's largest R&D and manufacturing footprints dedicated to complex chemical synthesis. Their capabilities include the production of a wide range of therapeutic agents, including high-potency compounds and controlled substances. In addition to supporting the internal product pipeline of Apotex, the company provides contract development and manufacturing organization (CDMO) services to external partners. Apotex Pharmachem maintains a significant global presence with additional facilities in India, ensuring a robust supply chain for essential medicines. Following the acquisition of Apotex by SK Capital Partners in 2023, the company continues to focus on expanding its portfolio of complex APIs.